{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T11:26:42Z","timestamp":1785324402949,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:00:00Z","timestamp":1748476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04260-y","type":"journal-article","created":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:17:26Z","timestamp":1748517446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Variant angina associated with a CGRP receptor antagonist: a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Hongki","family":"Jeon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Man","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,29]]},"reference":[{"issue":"5","key":"4260_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1046\/j.1468-2982.1994.1405320.x","volume":"14","author":"L Edvinsson","year":"1994","unstructured":"Edvinsson L, Goadsby PJ. Neuropeptides in migraine and cluster headache. Cephalalgia Oct. 1994;14(5):320\u20137. https:\/\/doi.org\/10.1046\/j.1468-2982.1994.1405320.x.","journal-title":"Cephalalgia Oct"},{"issue":"8","key":"4260_CR2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/s1474-4422(19)30185-1","volume":"18","author":"M Ashina","year":"2019","unstructured":"Ashina M, Hansen JM, Do TP, Melo-Carrillo A, Burstein R, Moskowitz MA. Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol Aug. 2019;18(8):795\u2013804. https:\/\/doi.org\/10.1016\/s1474-4422(19)30185-1.","journal-title":"Lancet Neurol Aug"},{"issue":"6","key":"4260_CR3","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol Jun. 2018;14(6):338\u201350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1.","journal-title":"Nat Rev Neurol Jun"},{"issue":"11","key":"4260_CR4","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/14737175.2024.2401558","volume":"24","author":"WD Wells-Gatnik","year":"2024","unstructured":"Wells-Gatnik WD, Pellesi L, Martelletti P. Rimegepant and Atogepant: novel drugs providing innovative opportunities in the management of migraine. Expert Rev Neurother Nov. 2024;24(11):1107\u201317. https:\/\/doi.org\/10.1080\/14737175.2024.2401558.","journal-title":"Expert Rev Neurother Nov"},{"issue":"7","key":"4260_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17460441.2024.2365379","volume":"19","author":"C Baraldi","year":"2024","unstructured":"Baraldi C, Beier D, Martelletti P, Pellesi L. The preclinical discovery and development of Atogepant for migraine prophylaxis. Expert Opin Drug Discov Jul. 2024;19(7):783\u20138. https:\/\/doi.org\/10.1080\/17460441.2024.2365379.","journal-title":"Expert Opin Drug Discov Jul"},{"issue":"1","key":"4260_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/heartjnl-2022-321268","volume":"13","author":"JF Beltrame","year":"2022","unstructured":"Beltrame JF. Management of vasospastic angina. Heart Dec. 2022;13(1):70\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2022-321268.","journal-title":"Heart Dec"},{"issue":"16","key":"4260_CR7","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1161\/circulationaha.111.037283","volume":"18","author":"GA Lanza","year":"2011","unstructured":"Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation Oct. 2011;18(16):1774\u201382. https:\/\/doi.org\/10.1161\/circulationaha.111.037283.","journal-title":"Circulation Oct"},{"key":"4260_CR8","doi-asserted-by":"publisher","unstructured":"MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. Jul 7. 1998;98(1):25\u201330. https:\/\/doi.org\/10.1161\/01.cir.98.1.25","DOI":"10.1161\/01.cir.98.1.25"},{"issue":"4","key":"4260_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/01.wnf.0000136889.78887.6f","volume":"27","author":"S Wasson","year":"2004","unstructured":"Wasson S, Jayam VK. Coronary vasospasm and myocardial infarction induced by oral Sumatriptan. Clin Neuropharmacol Jul-Aug. 2004;27(4):198\u2013200. https:\/\/doi.org\/10.1097\/01.wnf.0000136889.78887.6f.","journal-title":"Clin Neuropharmacol Jul-Aug"},{"issue":"10","key":"4260_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","volume":"6","author":"TW Ho","year":"2010","unstructured":"Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol Oct. 2010;6(10):573\u201382. https:\/\/doi.org\/10.1038\/nrneurol.2010.127.","journal-title":"Nat Rev Neurol Oct"},{"issue":"1","key":"4260_CR11","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s10194-024-01753-y","volume":"5","author":"R Oliveira","year":"2024","unstructured":"Oliveira R, Gil-Gouveia R, Puledda F. CGRP-targeted medication in chronic migraine - systematic review. J Headache Pain Apr. 2024;5(1):51. https:\/\/doi.org\/10.1186\/s10194-024-01753-y.","journal-title":"J Headache Pain Apr"},{"issue":"3","key":"4260_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1161\/01.res.73.3.579","volume":"73","author":"S Gulbenkian","year":"1993","unstructured":"Gulbenkian S, Saetrum Opgaard O, Ekman R, et al. Peptidergic innervation of human epicardial coronary arteries. Circ Res Sep. 1993;73(3):579\u201388. https:\/\/doi.org\/10.1161\/01.res.73.3.579.","journal-title":"Circ Res Sep"},{"issue":"6","key":"4260_CR13","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1016\/0002-8703(92)90054-y","volume":"124","author":"P Lechleitner","year":"1992","unstructured":"Lechleitner P, Genser N, Mair J, et al. Calcitonin gene-related peptide in patients with and without early reperfusion after acute myocardial infarction. Am Heart J Dec. 1992;124(6):1433\u20139. https:\/\/doi.org\/10.1016\/0002-8703(92)90054-y.","journal-title":"Am Heart J Dec"},{"key":"4260_CR14","first-page":"1","volume":"569","author":"A Franco-Cereceda","year":"1988","unstructured":"Franco-Cereceda A. Calcitonin gene-related peptide and tachykinins in relation to local sensory control of cardiac contractility and coronary vascular tone. Acta Physiol Scand Suppl. 1988;569:1\u201363.","journal-title":"Acta Physiol Scand Suppl"},{"issue":"4","key":"4260_CR15","first-page":"186","volume":"44","author":"M Locatelli","year":"2000","unstructured":"Locatelli M. The importance of substance P and calcitonin gene related peptide as vasodilator neuropeptide during acute phase of experimental posthemorrhagic vasospasm. J Neurosurg Sci Dec. 2000;44(4):186\u201391.","journal-title":"J Neurosurg Sci Dec"},{"issue":"1","key":"4260_CR16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1124\/jpet.102.037754","volume":"304","author":"P Hasbak","year":"2003","unstructured":"Hasbak P, Saetrum Opgaard O, Eskesen K, Schifter S, Arendrup H, Longmore J, Edvinsson L. Investigation of CGRP receptors and peptide Pharmacology in human coronary arteries. Characterization with a nonpeptide antagonist. J Pharmacol Exp Ther Jan. 2003;304(1):326\u201333. https:\/\/doi.org\/10.1124\/jpet.102.037754.","journal-title":"J Pharmacol Exp Ther Jan"},{"issue":"7","key":"4260_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/phar.2706","volume":"42","author":"J Perino","year":"2022","unstructured":"Perino J, Corand V, Laurent E, et al. Myocardial infarction associated with erenumab: A case report. Pharmacotherapy Jul. 2022;42(7):585\u20139. https:\/\/doi.org\/10.1002\/phar.2706.","journal-title":"Pharmacotherapy Jul"},{"issue":"23","key":"4260_CR18","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa1813049","volume":"5","author":"DW Dodick","year":"2019","unstructured":"Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the treatment of migraine. N Engl J Med Dec. 2019;5(23):2230\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1813049.","journal-title":"N Engl J Med Dec"},{"issue":"10200","key":"4260_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"31","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of Rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet Aug. 2019;31(10200):737\u201345. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x.","journal-title":"Lancet Aug"},{"issue":"8","key":"4260_CR20","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/NEJMoa2035908","volume":"19","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med Aug. 2021;19(8):695\u2013706. https:\/\/doi.org\/10.1056\/NEJMoa2035908.","journal-title":"N Engl J Med Aug"},{"issue":"8","key":"4260_CR21","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1161\/CIRCRESAHA.123.321752","volume":"132","author":"CCFMJ Baaten","year":"2023","unstructured":"Baaten CCFMJ, Vondenhoff S, Noels H. Endothelial cell dysfunction and increased cardiovascular risk in patients with chronic kidney disease. Circul Res. 2023;132(8):970\u201392. https:\/\/doi.org\/10.1161\/CIRCRESAHA.123.321752.","journal-title":"Circul Res"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04260-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04260-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T11:17:26Z","timestamp":1748517446000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04260-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,29]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4260"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04260-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,29]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors confirm that written consent for submission and publication of this case report has been obtained from the patient in line with COPE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}